During the past decade, Chuv Bh-04 conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chuv Bh-04" #1 collaborator was "Juno" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Chuv Bh-04" are "Eosinophilic Esophagitis" (2 trials), "Precursor Cell Lymphoblastic Leukemia-Lymphoma" (1 trials) and "Psoriatic Arthritis" (1 trials). Many other conditions were trialed in "Chuv Bh-04" in a lesser frequency.

Most popular intervention types in "Chuv Bh-04" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "CC-93538" (2 trials), "Placebo" (2 trials), "Apremilast 20mg" (1 trials), "Apremilast 30mg" (1 trials) and "JCAR015" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chuv Bh-04" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Chuv Bh-04". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Chuv Bh-04, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Chuv Bh-04, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".